Advanced hepatocellular carcinoma treatment strategies:Are transarterial approaches leading the way?  

作　　者：Stefan Patauner Giovanni Scotton Francesca Notte Antonio Frena 

机构地区：[1]Department of General and Pediatric Surgery,Bolzano Central Hospital-SABES,Bolzano 39100,Trentino-Alto Adige,Italy

出　　处：《World Journal of Gastrointestinal Oncology》2025年第1期22-27,共6页世界胃肠肿瘤学杂志（英文）

摘　　要：Hepatocellular carcinoma(HCC)is a leading cause of cancer-related mortality worldwide,with advanced stages posing significant treatment challenges.Al-though hepatic arterial infusion chemotherapy(HAIC)has emerged as a promising modality for treating advanced HCC,particularly in Asian clinical practice,its adoption in Western medicine remains limited due to a lack of large-scale randomized controlled trials.This editorial reviews and comments on the meta-analysis conducted by Zhou et al,which evaluates the efficacy and safety of HAIC and its combination strategies for advanced HCC.The authors performed a comprehensive meta-analysis of various clinical trials and cohort studies comparing HAIC and its combinations to other first-line treatments,such as sorafenib and transarterial chemoembolization(TACE).In this work,HAIC showed significantly better results regarding overall survival and progression-free survival compared to sorafenib or TACE alone and their combination.HAIC in combination with lenvatinib,ablation,programmed cell death 1 inhibitors,and radiotherapy further enhanced patient outcomes,indicating a synergistic effect.This editorial focuses on the critical role of multimodal treatment strategies in managing advanced HCC.It advocates for a paradigm shift towards integrated treatment approaches to enhance survival rates and improve the quality of life in patients with advanced HCC.

关 键 词：Hepatocellular carcinoma Hepatic arterial infusion chemotherapy Transarterial chemoembolization SORAFENIB Combined therapy 

分 类 号：R735.7[医药卫生—肿瘤]